TNF blocker adalimumab approved for pediatric Crohn’s disease

The tumor necrosis factor blocker adalimumab is now approved for treating children with Crohn’s disease, down to age 6 years, AbbVie, the manufacturer, announced on Sept. 25.

The approved...